Lessons learned from Steve Jobs' illness and public disclosureWhen the head of a New York-based investment firm was hospitalized for a heart condition, the executive took a very different approach from Apple co-founder Steve Jobs' own health-related disclosure.
Lazard CEO Bruce Wasserstein felt little push-back from investors after he recently issued a short but poignant message, stating that he was hospitalized for an irregular heartbeat. "His condition is serious," the note said, "but he is stable and recovering."
It was a very different approach from the one taken at Apple early this year. In January, after months of rumors with no public response, Jobs ceded control of day-to-day operations. He returned to work in June after receiving a liver transplant.
In a new report from The Wall Street Journal, Michael Corkery examined the effect differing levels of disclosure had on the stock prices of both companies. His conclusion: "Openness can be healthy."
"The computer makers shares see-sawed when investors worried that the company was being less than forthcoming about the health of CEO Steve Jobs," the report said.
Apples secrecy surrounding the health of Jobs has had a major effect on Apple's stock price, while the open stance of Lazard resulted in a 1 percent drop. Throughout Jobs' career, Apple has been notoriously tight-lipped about the health of its chief and has always rebutted any questions about his health as being a "private matter." The report suggested that Wasserstein's more forthcoming approach was to his company's benefit.
"A CEO doesnt want his company's stock price to go up when he gets sick because it means investors dont consider him a critical asset," Corkery wrote. "But he doesnt want it to tank either. By being straightforward about Wassersteins illness, Lazard is enabling investors to decide for themselves about the possibility of a leadership change at the storied firm."
Jobs began to buck his secrecy trend at the beginning of this year with his open letter to Apple fans about his apparent weight loss and failure to show at the Macworld keynote. When he returned to the stage at Apples annual music event in September, Jobs acknowledged his health.
"So, Im vertical, Im back at Apple and loving every minute of it," he said, "and working with some talented teams to come up with some great products for the future."
On Topic: Investor
- Morgan Stanley raises Apple target to $160, citing strength as a 'platform company'
- German investment firm Berenberg predicts doom for Apple, sets price target of $60
- Apple closes in on $775B market cap, now twice as large as No. 2 Exxon Mobil
- Apple remains institutional investors' most-loved stock with $383B in holdings
- RBC says Apple could fund $65B+ annual capital return program, raises target to $140